epa_echo
2 records
fda
1 records
FDA Drug Recall: Taztia XT(diltiazem HCI extended release capsules, USP, Once-A-Day Dosage, 360 m
2013-02-13
Class II — Failed Dissolution Specification: Out of a specification result occurred during the 3-month stability testing. Dissolution result at the 4-hour time point was 41% (specification: 20-40%).
View Source
ftc_enforcement
4 records
Watson Pharmaceuticals, Inc., et al. (FTC v. Actavis)
2019-02-28
FTC live enforcement action FY2019; matched respondent 'Watson Pharmaceuticals, Inc., (FTC v. Actavis)'
View Source
Watson Pharmaceuticals, Inc., a corporation, and Robin Hood Holdings Limited, a limited liability company, In the Matter of
2010-01-19
FTC live enforcement action FY2010; matched respondent 'Watson Pharmaceuticals, Inc.'
View Source
Watson Pharmaceuticals, Inc. and Andrx Corporation., In the Matter of
2006-12-12
FTC live enforcement action FY2006; matched respondent 'Watson Pharmaceuticals, Inc.'
View Source
Watson Pharmaceuticals, Inc / Andrx
2006-10-31
FTC merger enforcement action FY2007 matter 610139; matched respondent 'Watson Pharmaceuticals, Inc'
View Source
Be informed when major changes happen on C.F.A.I. — new data sources, platform updates, critical enforcement alerts
No spam. Only major updates. Unsubscribe anytime.